Related Experiment Video
Updated: Mar 15, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against
Yan-Ruide Li1,2, Miao Li3,4, Yuning Chen3,4
1Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, USA. charlie.li@ucla.edu.
Abstract:
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapies have demonstrated remarkable efficacy in hematologic malignancies; however, their clinical performance in solid tumors remains limited due to suboptimal tumor infiltration, antigen heterogeneity, and immunosuppressive tumor microenvironments (TME). Invariant natural killer T (NKT) cells have recently emerged as a promising alternative platform for CAR engineering, owing to their intrinsic tissue-homing capacity, multi-modal cytotoxicity, and ability to reshape the TME. In this study, we performed a comprehensive preclinical comparison of conventional CAR-T cells and allogeneic stem cell-derived IL-15-enhanced CAR-NKT cells in solid tumor models, integrating spatiotemporal transcriptomic profiling across multiple tissues and longitudinal time points. Our analyses revealed distinct in vivo pharmacokinetic, pharmacodynamic, and immunoregulatory profiles between the two cell therapy modalities. Compared with CAR-T cells, CAR-NKT cells demonstrated superior homing, infiltration, and localization within solid tumors, along with prolonged in vivo persistence and a unique immune checkpoint receptor expression landscape. Notably, CAR-T cells exhibited synergistic antitumor responses when combined with TIGIT blockade, whereas CAR-NKT cells showed greater sensitivity to CD96 blockade in vivo. These findings highlight the divergent therapeutic dynamics of CAR-T and CAR-NKT cells and provide mechanistic insights that inform the rational design of next-generation cell therapies and combinatorial strategies for solid tumors.
Insights
Chimeric antigen receptor (CAR)-engineered NKT cells show improved solid tumor infiltration and persistence compared to CAR-T cells. This study reveals distinct therapeutic dynamics and informs next-generation cell therapy design for solid tumors.
Area of Science:
- Immunotherapy
- Cellular Therapy
- Oncology
Background:
- Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy shows promise in hematologic cancers but faces challenges in solid tumors, including poor infiltration and immunosuppressive tumor microenvironments (TME).
- Invariant natural killer T (NKT) cells offer potential advantages for CAR engineering due to their tissue-homing abilities, inherent cytotoxicity, and TME-modulating capacity.
Purpose of the Study:
- To conduct a preclinical comparison of CAR-T cells and IL-15-enhanced CAR-NKT cells in solid tumor models.
- To investigate the distinct in vivo pharmacokinetic, pharmacodynamic, and immunoregulatory profiles of these cell therapy modalities.
Main Methods:
- Utilized solid tumor models for preclinical comparison.
- Integrated spatiotemporal transcriptomic profiling across multiple tissues and time points.
- Analyzed in vivo homing, infiltration, persistence, and immune checkpoint receptor expression.
Main Results:
- CAR-NKT cells exhibited superior homing, infiltration, and tumor localization compared to CAR-T cells.
- CAR-NKT cells demonstrated prolonged in vivo persistence and a unique immune checkpoint profile.
- CAR-T cells synergized with TIGIT blockade, while CAR-NKT cells were more sensitive to CD96 blockade.
Conclusions:
- CAR-T and CAR-NKT cells possess divergent therapeutic dynamics in solid tumors.
- Findings provide mechanistic insights for designing next-generation CAR-based immunotherapies and combination strategies for solid tumors.
